EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS
Kanamycin
CLASS
Aminoglycoside
MECHANISM OF ACTION
Bactericidal effect
DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)
Experimental
MODE OF ADMINISTRATION
Injectable
LINK TO PUBMED
https://pubmed.ncbi.nlm.nih.gov/25668636/
SIMILAR TARGETS IN OTHER SPECIES
30S ribosomal subunit (binding sites vary for each aminoglycoside) ~ Escherichia coli (strain K12)
DRUG BANK ID
DB01172
EXTERNAL LINKS
Human Metabolome Database HMDB0015303 KEGG Compound C01822 PubChem Compound 6032 PubChem Substance 46508178 ChemSpider 5810 BindingDB 50031282 RxNav 6099 ChEBI 17630 ChEMBL CHEMBL1384 ZINC ZINC000008214590 Drugs.com Drugs.com Drug Page https://www.drugs.com/cdi/kanamycin.html Wikipedia Kanamycin_A
REFERENCE
Dreyer, A., R?ltgen, K., Dangy, J. P., Ruf, M. T., Scherr, N., Bolz, M., Tobias, N. J., Moes, C., Vettiger, A., Stinear, T. P., & Pluschke, G. (2015). Identification of the Mycobacterium ulcerans protein MUL_3720 as a promising target for the development of a diagnostic test for Buruli ulcer. PLoS Neglected Tropical Diseases, 9(2). https://doi.org/10.1371/JOURNAL.PNTD.0003477